Trials / Completed
CompletedNCT06027437
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Previous MyoKardia Formulation of Danicamtiv and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the relative biological availability and the effect of food on the drug levels of Danicamtiv in health adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Danicamtiv | Specified dose on specified days. |
Timeline
- Start date
- 2023-09-05
- Primary completion
- 2023-11-10
- Completion
- 2023-11-10
- First posted
- 2023-09-07
- Last updated
- 2023-11-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06027437. Inclusion in this directory is not an endorsement.